yS-T cells are a rare subpopulation of T lymphocytes with unique antitumor properties. Cancerous cells - particularly those of epithelial origin - are nowknown to display a variety of stress-induced antigens (such as MICA/B), which can serve as recognition determinants for the human y8-T cell receptor (TCR) and associated accessory molecules. Thus, in order to kill tumor cells, y8-T cells do not require the presence of tumor-specific antigens, tumor antigen processing or major histocompatibility complex (MHC) display of tumor-specific peptides. Given this, we propose that y8-T cells are ideal to study in the context of developing novel approaches for the primary or adjuvant treatment of a number of common human cancers of epithelial origin - including breast cancer. Nevertheless, despite the theoretical promise of y8-T cell-based immunotherapy, to date clinical studies to examine this question are only now in the earliest stages of development. Indeed, until very recently, no practical means existed to generate the large numbers of y8-T cells required for clinical-scale administration. Rationale: We initially identified a CD2-initiated signaling pathway which inhibits apoptosis in mitogen-stimulated human y8-T cells. By exploiting this signaling pathway, our laboratory has pioneered the development of the methods permitting the large-scale ex vivo expansion of human y8-T cells. Importantly, these y8-T cells retain potent innate antitumor activity in vitro against a variety of human tumor cell lines, including breast cancer cell lines. In addition, our preliminary studies demonstrate that when administered intravenously, these y5-T cells can inhibit the growth of human breast cancer tumors established in nude mice. Together, these findings provide both the biological and clinical rationale for the studies proposed in this grant. Approach:
The aims of this proposal are as follows.
Aim 1 : To characterize the y8-T cell population present in breast cancer patients in regard to numbers in the circulation, their ability to be expanded ex vivo and their cytotoxicity to breast cancer cells.
Aim 2 : To optimize and standardize the large-scale expansion and purification of human y5-T cells for subsequent use in clinical trials. Studies from this aim will yield an IND application to be filed with the US FDA.
Aim 3 : To examine and optimize expanded human yS-T cell immunotherapy in a human xenogeneic breast cancer model.
Aim 4 : To initiate clinical trials of y8-T cell immunotherapy in patients with therapy-resistant metastatic breast cancer. Long-term objectives: We propose to follow our first-generation trial with subsequent Phase I studies that will combine the y5-T cell regimen with immunomodulatoryagents and/or chemotherapy based on observations made in our animal models. These studies would then form the basis for future Phase II trials incorporating such treatment strategies. Lay description: y8-T cells are a rare type of blood cell which can naturally kill cancer cells making them ideal to study as a new form of cancer therapy. However, they are extremely difficult to grow in the laboratory. As we have discovered a means to generate large numbers of these cells, we are now able to propose clinical studies designed to examine how these rare tumor-killing cells might be used as a newform of treatment for breast cancer - or other types of cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA089019-07
Application #
7680148
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
7
Fiscal Year
2008
Total Cost
$324,240
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Li, Rong; Zhang, Kui; Penedo, Thuy Linh et al. (2016) The RANK Pathway in Advanced Breast Cancer: Does Src Play a Role? Appl Immunohistochem Mol Morphol 24:42-50
Walters, Beth; Thompson, Sunnie R (2016) Cap-Independent Translational Control of Carcinogenesis. Front Oncol 6:128
Forero, Andres; Li, Yufeng; Chen, Dongquan et al. (2016) Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes. Cancer Immunol Res 4:390-9
Wu, Lizhi; Chaudhary, Sandeep C; Atigadda, Venkatram R et al. (2016) Retinoid X Receptor Agonists Upregulate Genes Responsible for the Biosynthesis of All-Trans-Retinoic Acid in Human Epidermis. PLoS One 11:e0153556
Atherton, Daniel S; Sexton, Katherine C; Otali, Dennis et al. (2016) Factors Affecting the Use of Human Tissues in Biomedical Research: Implications in the Design and Operation of a Biorepository. Methods Mol Biol 1381:1-38
McNally, Lacey R; Mezera, Megan; Morgan, Desiree E et al. (2016) Current and Emerging Clinical Applications of Multispectral Optoacoustic Tomography (MSOT) in Oncology. Clin Cancer Res 22:3432-9
Stanley, Jennifer; Klepczyk, Lisa; Keene, Kimberly et al. (2015) PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers. Breast Cancer Res Treat 150:569-79
Forero-Torres, Andres; Varley, Katherine E; Abramson, Vandana G et al. (2015) TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clin Cancer Res 21:2722-9
Atigadda, Venkatram R; Xia, Gang; Deshpande, Anil et al. (2015) Conformationally Defined Rexinoids and Their Efficacy in the Prevention of Mammary Cancers. J Med Chem 58:7763-74
Putcha, Balananda-Dhurjati Kumar; Jia, Xu; Katkoori, Venkat Rao et al. (2015) Clinical Implications of Rabphillin-3A-Like Gene Alterations in Breast Cancer. PLoS One 10:e0129216

Showing the most recent 10 out of 208 publications